Harmony Biosciences Q3 WAKIX sales about $239 million; 2025 revenue guidance raised
Harmony Biosciences said preliminary third-quarter 2025 net revenue for the WAKIX franchise was about $239 million, up 29% year over year, and raised its 2025 revenue guidance to $845 million-$865 million from $820 million-$860 million. The figures are preliminary and unaudited, and the company will report full third-quarter results on November 4, 2025.
Key points
- WAKIX franchise net revenue of about $239 million in Q3 2025, up 29% year over year
- Average patients reached 8,100 in Q3 2025, an increase of about 500 for the quarter
- 2025 revenue guidance raised to $845 million-$865 million from $820 million-$860 million
- Results are preliminary and unaudited; full Q3 2025 results and conference call set for November 4, 2025
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.